Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
暂无分享,去创建一个
P. Spagnolo | V. Cottin | E. van Ganse | M. Belhassen | K. Kirchgässler | P. Bonniaud | F. Dalon | M. Nolin
暂无分享,去创建一个
P. Spagnolo | V. Cottin | E. van Ganse | M. Belhassen | K. Kirchgässler | P. Bonniaud | F. Dalon | M. Nolin